
With the licensing of the first zzso necrosis factor zzso zzso independent zzso but zzso drug registers were set up by the national rheumatology societies in several European countries in order to monitor the long-term safety and effectiveness of this new generation of zzso Even though different in some respects of study design and monitoring, the registers share a number of common features: they include all licensed biological agents, they observe the patients for a defined period of time or indefinitely irrespective of the drug given and they use zzso zzso or national registers in order to put the results into zzso The registers have been collaborating closely since zzso Three of them (the zzso Swedish and German zzso have agreed on a zzso reporting system of adverse events which ensures a high and uniform quality of data submitted to the companies, who subsequently report to the drug regulatory authorities, enabling regulatory requirements on safety surveillance to be zzso In the present work, major results on drug safety with regard to infections, zzso cardiovascular events, pregnancy outcomes and deaths are zzso With an increasing number of new drugs and multiple zzso of individual patients the assignment of events to specific treatments will become zzso zzso This and other zzso challenges and the approaches to cope with them are zzso A growing dialogue between drug regulatory authorities, academic medicine and companies in order to make best use of the zzso of zzso drug registers as new tools for zzso with currently described rheumatology registers as prototypes is zzso 

